CERO THERAPEUTICS HOLDINGS, INC. Unamortized Debt Issuance Expense
CERO THERAPEUTICS HOLDINGS, INC. (CERO) had Unamortized Debt Issuance Expense of $517.15 thousand as of 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Balance Sheet › Assets › Assets, Noncurrent
us-gaap:UnamortizedDebtIssuanceExpense · last filed 2026-08-14
- 2026-06-30: Unamortized Debt Issuance Expense $517.15K.
- 2026-03-31: Unamortized Debt Issuance Expense $1.32M.
- 2025-12-31: Unamortized Debt Issuance Expense $771.09K.
- 2025-09-30: Unamortized Debt Issuance Expense $1.03M.
| Period end | Unamortized Debt Issuance Expense |
|---|---|
| 2026-06-30 | $517.15K 10-Q · filed 2026-08-14 |
| 2026-03-31 | $1.32M 10-Q · filed 2026-05-15 |
| 2025-12-31 | $771.09K 10-K · filed 2026-04-15 |
| 2025-09-30 | $1.03M 10-Q · filed 2025-11-19 |
| 2025-06-30 | $1.38M 10-Q · filed 2025-08-22 |
| 2025-03-31 | $1.21M 10-Q · filed 2025-05-15 |
| 2024-12-31 | $1.01M 10-K · filed 2025-04-15 |
| 2024-09-30 | $1.50M 10-Q/A · filed 2024-11-20 |
| 2024-06-30 | $3.80M 10-Q · filed 2024-08-14 |
| 2024-03-31 | $4.80M 10-Q · filed 2024-05-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. (CELZ) | United States | $0.006B | |
| AIM ImmunoTech Inc. (AIM) | United States | $0.006B | |
| TScan Therapeutics, Inc. (TCRX) | United States | $0.008B | -1.23 |
| PharmaCyte Biotech, Inc. (PMCB) | United States | $0.005B | |
| WINDTREE THERAPEUTICS INC /DE/ (WINT) | United States | $0.003B | -0.32 |
| VivoSim Labs, INC. (VIVS) | United States | $0.003B | |
| Senti Biosciences Holdings, Inc. (SNTI) | United States | $0.011B | -0.70 |
| Calidi Biotherapeutics, Inc. (CLDI) | United States | $0.003B | |
| IN8BIO, INC. (INAB) | United States | $0.012B | -0.76 |
| CURIS INC (CRIS) | United States | $0.002B | -0.05 |